tbuckley/cabot-search huggingface dataset:
Three lines of targeted therapy for metastatic renal cell carcinoma (mRCC): A viable strategy?
Authors: Tomas Buchler, Zbynek Bortlicek, Alexandr Poprach, Katerina Kubackova, Igor Kiss, Milada Zemanova, Ondrej Fiala, Jitka Abrahamova, Bohuslav Melichar
Journal: Journal of Clinical Oncology (2013)

e15581 Background: Sequential therapy with tyrosine kinase inhibitors (TKIs) and the mTOR inhibitor everolimus has been proposed for mRCC. The aim of the present retrospective analysis was to compare the efficacy of everolimus used after one versus two prior TKIs and to assess the progress of a defined cohort of patients (pts) through sequential lines of therapy. Methods: In the national database of mRCC pts treated with targeted agents 368 pts received everolimus as the 2nd (N=269) or 3rd (N=99) targeted agents following TKIs sunitinib or sorafenib. Survival was calculated using the Kaplan-Meier method, and the differences were assessed using the Log-rank test. Furthermore, the treatment course was evaluated in 331 mRCC pts starting 1st line therapy with sunitinib or sorafenib in 2010. The data cut-off date was October 8, 2012. Results: Progression-free survival (PFS) for everolimus in the 2nd versus the 3rd line of targeted therapy was 6.5 months (95% confidence interval [95% CI] 5.3-7.7 months) versus 6.1 months (95% CI 4.0-8.3 months), respectively (P=0.159). The incidence and profile of adverse events were similar in both lines. PFS from the start of the first targeted agent to progression on the third targeted agent was similar for pts receiving three lines of therapy using the TKI-TKI-mTOR (N=99) and TKI-mTOR-TKI (N=17) sequence: 28.5 months (95% CI 25.2-31.7 months) versus 27.2 months (95% CI 24.0-30.4 months), respectively (P=0.281). The median follow-up for the initial cohort of 331 pts treated with sunitinib or sorafenib was 20.1 months. 152 pts (46%) subsequently received a 2nd line therapy, and 82 pts (25%) died before reaching the 2nd line. Of the 152 pts receiving the 2nd line therapy, only 38 pts (11%) went on to the 3rd line, and 46 pts (14%) died before reaching the 3rd line of therapy. The remaining pts still continued on 1st line (N=50; 15%) or 2nd line therapy (N=34; 10%), were lost to follow-up (N=30; 9%), or were alive but not receiving antineoplastic treatment (N=51; 15%). Conclusions: Everolimus has similar efficacy and toxicity whether used in the 2nd or the 3rd line of targeted therapy for mRCC. A minority of mRCC pts starting the 1st line targeted treatment can be expected to reach the 3rd line therapy.
CLO20-034: First U.S. Prospective Evaluation of Performance of 64Cu DOTATATE PET/CT in Somatostatin Expressing Neuroendocrine Tumors
Authors: E. S. Delpassand, Rodolfo Nunez, D. Ranganathan, N. Wagh, A. Shafie, A. Gaber, I. Tworowska, A. Abbasi
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-034: First U.S. Prospective Evaluation of Performance of 64Cu DOTATATE PET/CT in Somatostatin Expressing Neuroendocrine Tumors" published on 20 Mar 2020 by National Comprehensive Cancer Network.
NATIONAL INPATIENT SAMPLE DATABASE REVEALS PULMONARY ARTERY CATHETER USE DECREASES OUTCOMES BUT UNDERUSED IN WOMEN
Authors: Estefania Oliveros, Tisha Marie Suboc, Anupama Rao, Karolina Marinescu, Neelum Aggarwal, Annabelle Volgman
Journal: Journal of the American College of Cardiology (2020)
VALIDATION OF NON-CONTRAST MULTIPLE OVERLAPPING THIN SLAB 4D-FLOW CARDIAC MAGNETIC RESONANCE IMAGING
Authors: Nina Rashedi, Luis Landeras, Victor Mor-Avi, Davide Genovese, Peng Lai, Wang Haonan, Kalie Kebed, Isla McClelland, Anja Brau, Martin Janich, Roberto Lang, Amit R. Patel
Journal: Journal of the American College of Cardiology (2020)
Kidney disease is associated with in-hospital death of patients with COVID-19
Authors: Yichun Cheng, Ran Luo, Kun Wang, Meng Zhang, Zhixiang Wang, Lei Dong, Junhua Li, Ying Yao, Shuwang Ge, Gang Xu
Journal: Kidney International (2020)

In December 2019, a coronavirus 2019 (COVID-19) disease outbreak occurred in Wuhan, Hubei Province, China, and rapidly spread to other areas worldwide. Although diffuse alveolar damage and acute respiratory failure were the main features, the involvement of other organs needs to be explored. Since information on kidney disease in patients with COVID-19 is limited, we determined the prevalence of acute kidney injury (AKI) in patients with COVID-19. Further, we evaluated the association between markers of abnormal kidney function and death in patients with COVID-19. This was a prospective cohort study of 701 patients with COVID-19 admitted in a tertiary teaching hospital that also encompassed three affiliates following this major outbreak in Wuhan in 2020 of whom 113 (16.1%) died in hospital. Median age of the patients was 63 years (interquartile range, 50-71), including 367 men and 334 women. On admission, 43.9% of patients had proteinuria and 26.7% had hematuria. The prevalence of elevated serum creatinine, elevated blood urea nitrogen and estimated glomerular filtration under 60 ml/min/1.73m2 were 14.4, 13.1 and 13.1%, respectively. During the study period, AKI occurred in 5.1% patients. Kaplan-Meier analysis demonstrated that patients with kidney disease had a significantly higher risk for in-hospital death. Cox proportional hazard regression confirmed that elevated baseline serum creatinine (hazard ratio: 2.10, 95% confidence interval: 1.36-3.26), elevated baseline blood urea nitrogen (3.97, 2.57-6.14), AKI stage 1 (1.90, 0.76-4.76), stage 2 (3.51, 1.49-8.26), stage 3 (4.38, 2.31-8.31), proteinuria 1+ (1.80, 0.81-4.00), 2+∼3+ (4.84, 2.00-11.70), and hematuria 1+ (2.99, 1.39-6.42), 2+∼3+ (5.56,2.58- 12.01) were independent risk factors for in-hospital death after adjusting for age, sex, disease severity, comorbidity and leukocyte count. Thus, our findings show the prevalence of kidney disease on admission and the development of AKI during hospitalization in patients with COVID-19 is high and is associated with in-hospital mortality. Hence, clinicians should increase their awareness of kidney disease in patients with severe COVID-19.
Dihydrofolate reductase as an oncogene: a microRNA binding site SNP leads to cellular transformation and drug resistance
Authors: Prasun Mishra, Pravin Mishra, Debabrata Banerjee, Joseph Bertino
Journal: Cancer Research (2008)

2458  Dihydrofolate Reductase (DHFR) is an E2F1-regulated enzyme that isessential for DNA synthesis and repair. Elevated levels of DHFR have been correlated with methotrexate resistance leading to poor prognosis in many cancers. We have previously demonstrated that a microRNA miR24 has a conserved binding site in DHFR 3’UTR and a miRSNP (microRNA binding site SNP) 829C→τ in DHFR 3’ UTR results in loss of miR24 function and leads to DHFR over expression and methotrexate resistance (Mishra et. al. 2007, PNAS). Of interest, we observed that DHFR over expressing CHO cells grow at a faster rate and form foci in monolayer cultures, which is a hallmark of transformation. Over expression of DHFR because of the SNP resulted in transformation of rat kidney cells (RK3) cells and murine fibroblast cells (NIH3T3) in vitro and in vivo in nude mice. To test the hypothesis that DHFR can be a potential proto-oncogene and when over expressed can act as an oncogene DHFR was over expressed in NIH3T3 and RK3 cells by a vector containing the DHFR coding region. Over-expression of DHFR transformed the immortalized non-transformed mammalian cells assayed by foci formation, anchorage independentgrowth and tumor formation in nude mice. Whereas the control vector alone transfected cells were not transformed.  We also over expressed DHFR in human mammary epithelial cells (MCF10A) and demonstrated that they now form colonies in soft agar. We next showed that DHFR over expression can make a breast cancer cell line (MDA-MB-231) more tumorigenic in nude mice. Using a clone of MDAMB231 cells that form subcutaneous tumors in a xenograft model only when co-injected with Matrigel, we demonstrated that DHFR over expression in these cells causes tumor formation without matrigel. Animals injected with DHFR over expressing breast cancer cells developed tumors (5/5) where as injection of control breast cancer cells did not result in tumor growth (0/5). To determine whether increased DHFR levels could be detected in aggressive human tumors, we isolated DNA from 51 metastatic human colorectal tumor samples and 7 peripheral blood mononuclear cells of non-cancer patients (as control) and examined them for DHFR gene copy number by Q-PCR. Interestingly, DHFR gene copy number was increased in the human colorectal cancer samples: 46 out of 51 samples had 1.6 to 18-fold increase in gene copy number of DHFR (mean 6.8). Our study demonstrates a novel role for dihydrofolate reductase, an essential DNA synthesis enzyme, as a proto-oncogene regulated by a microRNA miR24. This work also suggests a link between deregulated DNA synthesis and acquisition of a neoplastic phenotype.
Evaluation of combined modality treatment for advanced nasopharyngeal carcinoma by induction chemotherapy and radiotherapy
Authors: T. Q. Tran, V. V. Vu, D. K. Vo, K. C. Pham
Journal: Journal of Clinical Oncology (2006)

15544 Background: We performed a retrospective investigation of the combined induction chemotherapy and radiotherapy for advanced nasopharyngeal carcinomas at Cancer Center-Ho Chi Minh City-Vietnam. Method: In the period 1998–2000, the treatment regimen induced 2 or 3 cycles of cisplatin and 5-Fluorouracile followed by radiation. Cisplatin was given in the dose of 100 mg/m 2 /day 1 and 5FU 1,000 mg/m 2 /d1–4. Radiotherapy included 2 lateral cervical portals and an anterior cervical portal with Cobalt 60. Results: One hundred sixteen patients (92 men and 24 women) with age ranging from 15 to 72 years were enrolled. The overall response rate to induction chemotherapy was 66% (15% complete responses (CRs) and 51% partial responses (PRs)). After combined treatment, overall response rates was 92% (82% CRs, 10% PRs). Toxicities in the chemotherapy were mainly myelosuppression (40%), nausea/vomiting (27%), mucositis (28%), and diarrhea (12%). There was 9 recurrences (2 local, 7 distant), 7 deaths and 1 refusal of radiotherapy. Conclusion: The immediate local response rates was rather high despite of the common of major myelotoxicities and expensive cost. The long-term survival benefit need to be reevaluated carefully later. No significant financial relationships to disclose.
COMPARATIVE INCIDENCE AND COSTS ASSOCIATED WITH 30-DAY READMISSION FOR RECURRENT MI VERSUS MAJOR BLEEDING AMONG PATIENTS HOSPITALIZED WITH ACUTE MI IN THE UNITED STATES: A POPULATION-BASED COHORT STUDY
Authors: Sunny Goel, Michael Healy, Tarun Jain, Matthew Tomey, Jacqueline Tamis-Holland, Nitin Barman, Joseph Sweeny, Prathyusha Bande, Pooja Vijay, George D. Dangas, Roxana Mehran, Annapoorna Subhash Kini, Samin K. Sharma, Usman Baber
Journal: Journal of the American College of Cardiology (2020)
Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL)
Authors: Tait D. Shanafelt, Neil E. Kay, Sameer A. Parikh, Sara J. Achenbach, Connie E. Lesnick, Curtis A. Hanson, Geffen Kleinstern, Janet E. Olson, Aaron D. Norman, Kari G. Rabe, Susan M. Schwager, Timothy G. Call, Susan L. Slager
Journal: Leukemia (2020)
Volumetric parcellation of the cardiac right ventricle for regional geometric and functional assessment
Authors: Gabriel Bernardino, Amir Hodzic, Hélène Langet, Damien Legallois, Mathieu De Craene, Miguel Ángel González Ballester, Éric Saloux, Bart Bijnens
Journal: Medical Image Analysis (2021)

3D echocardiography is an increasingly popular tool for assessing cardiac remodelling in the right ventricle (RV). It allows quantification of the cardiac chambers without any geometric assumptions, which is the main weakness of 2D echocardiography. However, regional quantification of geometry and function is limited by the lower spatial and temporal resolution and the scarcity of identifiable anatomical landmarks, especially within the ventricular cavity. We developed a technique for regionally assessing the volume of 3 relevant RV volumetric regions: apical, inlet and outflow. The proposed parcellation method is based on the geodesic distances to anatomical landmarks that are easily identifiable in the images: the apex and the tricuspid and pulmonary valves, each associated to a region. Based on these distances, we define a partition in the endocardium at end-diastole (ED). This partition is then interpolated to the blood cavity using the Laplace equation, which allows to compute regional volumes. For obtaining an end-systole (ES) partition, the endocardial partition is transported from ED to ES using a commercial image-based tracking software, and then the interpolation process is repeated. We assessed the intra- and inter-observer reproducibility using a 10-subjects dataset containing repeated quantifications of the same images, obtaining intra- and inter- observer errors (7-12% and 10-23% respectively). Finally, we propose a novel synthetic mesh generation algorithm that deforms a template mesh imposing a user-defined strain to a template mesh. We used this method to create a new dataset for involving distinct types of remodelling that were used to assess the sensitivity of the parcellation method to identify volume changes affecting different parts. We show that the parcellation method is adequate for capturing local circumferential and global circumferential and longitudinal RV remodelling, which are the most clinically relevant cases.
Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: Results of TROG 02.02.
Authors: Jolie Ringash, Richard Fisher, Lester J. Peters, Brian O'Sullivan, Andy Trotti, Lizbeth M. Kenny, Richard J. Young, Danny Rischin
Journal: Journal of Clinical Oncology (2012)

5571 Background: We report the impact of p16 status on quality of life (QOL) for patients with stage III or IV (excluding T1-2N1 and M1) squamous cell carcinoma of the oropharynx (OPC) treated with concurrent chemoradiotherapy in a large international phase III trial (TROG 02.02/HeadSTART). Methods: The 861 patients accrued received definitive radiotherapy (RT) (70 Gy/7 weeks) concurrently with 3 cycles of either cisplatin (100mg/m 2 ) or cisplatin (75 mg/m 2 ) plus tirapazamine (290 mg/m 2 /day) by random assignment, as previously described. QOL was measured with the FACT-H&amp;N at baseline, 2,6,12, 23 and 38 months. No significant difference in overall or subscale QOL score change from baseline was observed between arms at any subsequent time point; results for the oropharynx subgroup by p16 status are reported for both treatment arms combined. Results: Of 853 eligible participants, 465 had OPC, for whom p16 status could be determined in 206. Of 179 who received adequate RT (≥ 60 Gy, no major deviations) and completed baseline QOL, 104 were p16+ and 79 were p16-. p16+ patients had better baseline ECOG PS, lower T-category, higher N-category, were younger and were less likely to be current smokers. Baseline mean FACT-H&amp;N score was statistically and clinically significantly better in p16+ patients (111 vs. 102, p=0.001). The drop in QOL from baseline to 2 months was more severe in p16+ cases (-20.4 vs -9.1, p=0.001), resulting in an equalization of 2 month scores (p16+: 90.6, p16-: 93.6, p=0.16). At 6 and 12 months post-treatment, no difference in score changes from baseline by p16 status was seen (6 mo, p16+: -6.2, p16 -:-1.2, p=0.22; 12 mo, p16 +: -0.3, p16 -: +2.0, p=0.82). Conclusions: p16 associated oropharyngeal cancer has been shown to be a distinct entity with different demographic features. In our study, such patients exhibited better baseline QOL and a more severe drop immediately after treatment, but did not differ in long-term QOL response to the effects of aggressive concurrent chemoradiation. Given the favorable prognosis of p16-associated oropharyngeal cancer, efforts to reduce the QOL burden of treatment are warranted.
Effect of Low-Frequency Repetitive Transcranial Magnetic Stimulation on Impulse Inhibition in Abstinent Patients With Methamphetamine Addiction
Authors: Jiajin Yuan, Weijun Liu, Qiongdan Liang, Xinyu Cao, Molly V. Lucas, Ti-Fei Yuan
Journal: JAMA Network Open (2020)

Impulsivity during periods of abstinence is a critical symptom of patients who use methamphetamine (MA).To evaluate changes in impulse inhibition elicited by repetitive transcranial magnetic stimulation (rTMS) in patients with MA addiction.This randomized clinical trial was conducted in Da Lian Shan Addiction Rehabilitation Center, Nanjing, China, from December 1, 2018, to April 20, 2019. Effects of the intervention were examined at 3 time points: after a single session (day 1), 24 hours after 10 repeated sessions (day 11), and at 3 weeks of follow-up (day 31). Men with MA addiction and healthy male control participants were recruited for this study. Data analysis was performed from March 2019 to October 2019.Patients who use MA were randomized to undergo sham rTMS (36 patients) and or 1-Hz rTMS (37 patients) to the left prefrontal cortex, receiving daily TMS treatments for 10 consecutive days.The primary outcome was impulse inhibition, which is primarily embodied by accuracy reduction (ie, accuracy cost) from standard to deviant trials in a 2-choice oddball task (80% standard and 20% deviant trials).The study included 73 men with MA addiction (mean [SD] age, 38.49 [7.69] years) and 33 male healthy control participants without MA addiction (mean [SD] age, 35.15 [9.68] years). The mean (SD) duration of abstinence for the men with MA addiction was 9.27 (4.61) months. Compared with the control group, patients with MA addiction exhibited greater impulsivity (accuracy cost, 3.3% vs 6.2%). The single session of 1-Hz rTMS over the left prefrontal cortex significantly increased accuracy from 91.4% to 95.7% (F1,36 = 9.58; P < .001) and reaction time delay from 50 milliseconds to 77 milliseconds (F1,36 = 22.66; P < .001) in deviant trials. These effects were seen consistently after 10 sessions of 1-Hz rTMS treatment (day 11 vs day 1, t26 = 1.59; P = .12), and the behavioral improvement was maintained at least for 3 weeks after treatment (day 31 vs day 1, t26 = 0.26; P = .80). These improvement effects of impulse inhibition were coupled with a reduction in addictive symptoms as measured by cue-induced craving. The pretest accuracy cost was positively correlated with the change in impulse inhibition (r = 0.615; P < .001) and change in craving (r = 0.334; P = .01), suggesting that these 2 behaviors may be modified simultaneously.These findings suggest that repeated rTMS sessions have sustained effects on impulse inhibition in patients with MA addiction and provide novel data on impulsivity management strategies for addiction rehabilitation.ChiCTR-ROC-16008541.
IMPACT OF BODY MASS INDEX ON OUTCOME AND HEALTH STATUS AFTER CHRONIC TOTAL OCCLUSION PCI: INSIGHTS FROM OPEN CTO REGISTRY
Authors: Taishi Hirai, Christian Patterson, William Nicholson, Dimitrios Karmpaliotis, Jeffrey Moses, Kensey Gosch, James Sapontis, James Aaron Grantham
Journal: Journal of the American College of Cardiology (2020)
In reflux-related heartburn unresponsive to PPIs, surgery increased treatment success vs active medical treatment
Authors: Vivek Kumbhari, Lawrence J. Cheskin
Journal: Annals of Internal Medicine (2020)

ACP Journal Club17 March 2020In reflux-related heartburn unresponsive to PPIs, surgery increased treatment success vs active medical treatmentVivek Kumbhari, MBChB, Lawrence J. Cheskin, MD, FACPVivek Kumbhari, MBChBJohns Hopkins Medical Institutions, Baltimore, Maryland, USA (V.K.)Search for more papers by this author, Lawrence J. Cheskin, MD, FACPGeorge Mason University, College of Health and Human Services, Fairfax, Virginia, USA (L.J.C.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ202003170-032 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationSpechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med. 2019;381:1513-23. https://pubmed.ncbi.nlm.nih.gov/31618539Clinical Impact RatingsGIM/FP/GP: Gastroenterology: Reference1 Campos GM, Peters JH, DeMeester TR, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg. 1999;3:292-300. [PMID: 10481122] Google Scholar Author, Article, and Disclosure InformationAffiliations: Johns Hopkins Medical Institutions, Baltimore, Maryland, USA (V.K.)George Mason University, College of Health and Human Services, Fairfax, Virginia, USA (L.J.C.)Disclosures: The commentators have disclosed no conflicts of interest. The forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-3040.This article was published at Annals.org on 3 March 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 March 2020Volume 172, Issue 6Page: JC32KeywordsCardiac surgeryGastroesophageal reflux diseaseHypersensitivityNumber needed to treatProton pump inhibitorsQuality of lifeQuestionnairesRandomized trialsRelative riskSurgery ePublished: 17 March 2020 Issue Published: 17 March 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
Authors: Tracey G. Simon, Ann-Sofi Duberg, Soo Aleman, Raymond T. Chung, Andrew T. Chan, Jonas F. Ludvigsson
Journal: New England Journal of Medicine (2020)

More information is needed about the long-term effects of low-dose aspirin (≤160 mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection.
FLOW-MEDIATED SKIN FLUORESCENCE (FMSF): A NOVEL METHOD FOR THE ESTIMATION OF SLEEP APNEA RISK IN HEALTHY PERSONS AND CARDIAC PATIENTS
Authors: Tomasz Rechcinski, Urszula Cieslik-Guerra, Patryk Siedlecki, Ewa Trzos, Karina A. Wierzbowska-Drabik, Ewa Szymczyk, Paulina Wejner-Mik, Malgorzata Kurpesa, Piotr Lipiec, Jaroslaw D Kasprzak
Journal: Journal of the American College of Cardiology (2020)
ULTRASOUND ASSISTED CATHETER DIRECTED THROMBOLYSIS CAN BE USED WITH EXTRA-CORPOREAL MEMBRANE OXYGENATION FOR THE SAFE AND EFFECTIVE TREATMENT OF MASSIVE PULMONARY EMBOLISM AND PULMONARY EMBOLISM IN TRANSIT
Authors: Saad Sikanderkhel, Lowell Ketron, Rafay Khan, Alison Bailey, Matthew Wiisanen
Journal: Journal of the American College of Cardiology (2020)
THE IMPACT OF ATRIAL FIBRILLATION BURDEN ON CRYOBALLOON ABLATION OUTCOMES FOR PAROXYSMAL ATRIAL FIBRILLATION
Authors: Abhishek Bose, Parag Anilkumar Chevli, Zeba Hashmath, Ajay K. Mishra, Gregory Berberian, Ghasan Ahmad, Jerzy Januszkiewicz, Douglas Laidlaw
Journal: Journal of the American College of Cardiology (2020)
Candidiasis in heroin abusers.
Journal: BMJ (1983)

muscular 29 year old man, was admitted with a high body temperature, tachycardia, and peripheral circulatory failure with a metabolic acidosis.Over the next six hours the metabolic acidosis progressed and he developed wide- spread haemorrhages in muscle and in mucous membranes and skin.On further inquiry we note he was found to have hypertonicity of muscles and hyperreflexia.Also, just before the terminal cardiac arrest he was severely acidotic with a pH of 7 08 and a base excess of -19 7. The serum lactate concentration at that time was raised at 2 9 mmol/l (26-1 mg/100 ml) (normal 1-8 mmol/l (16 2 mg/100 ml)).We believe that malignant hyperpyrexia could explain the clinical findings.This diagnosis carries an important therapeutic implication, as dantrolene has been shown to be effective in treating this condition.
IMPACT OF ANTI RETROVIRAL THERAPY ON CARDIAC GEOMETRY AND FUNCTION IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS
Authors: Alvaro Garcia-Arenas, Alaa M. Omar, Jeirym Miranda Tejada, Oscar Milian, Opeoluwa Dehinbo, Murli Udharam Purswani, Jonathan N. Bella
Journal: Journal of the American College of Cardiology (2020)